Skip Ribbon Commands
Skip to main content

​​​​​​​

​​

Primary Diagnosis

Heart Failure

Stu​dy Purpose​

To test the safety and efficacy of Empagliflozin compared to a placebo in patients with chronic heart failure.

Principal Investigator: Marcus McKenzie, MD

Trial Details

Locations: Legacy Heart Center Plano, Congestive Heart Failure Center Plano, The Heart Group Plano, and The Heart Group McKinney​

Sponsor: Boehringer Ingelheim

IRB Number: 017-067

Trial Status: Enrolling

Exclusions: Adults only

Change in Care: Participating will change your care

Contact Information:

Alexandria Biberstein
469.814.4732
Alexandria.Biberstein@BSWHealth.org

Full Protocol Title

A phase III randomized, double-blind trial to evaluate efficacy and safety of once daily empagliflozin 10mg compared to placebo, in patients with chronic Heart Failure with preserved Ejection Fraction (HFpEF).

Get Detailed Informatio​n On Clinicaltrials.gov »​​​​​​​​​​​​​​​​​

​​

​​

​​​​​​​​​​BAYLOR SCOTT & WHITE RESEARCH ​INSTITUTE​​